STOCK TITAN

Impel Pharmaceuticals Inc - IMPL STOCK NEWS

Welcome to our dedicated news page for Impel Pharmaceuticals (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Impel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Impel Pharmaceuticals's position in the market.

Rhea-AI Summary
Impel Pharmaceuticals Inc. (OTCQX: IMPL) is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the 'stalking horse' bidder to acquire the Company and its assets. The decision to file for Chapter 11 protection follows the strategic review process that Impel announced in October 2023, during which the Company explored a wide range of options including a potential sale of assets, a sale of the entire company, a merger, or other strategic transactions. The Company intends to continue operating as usual throughout the court-supervised sale process and has appointed a Chief Restructuring Officer to lead the financial and operational restructuring matters. Impel seeks to complete the sale process in the first quarter of 2024, with any sale subject to Court approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.27%
Tags
none
-
Rhea-AI Summary
Impel Pharmaceuticals Inc. announces exploration of strategic alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.71%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.55%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
management
Impel Pharmaceuticals Inc

OTC:IMPL

IMPL Rankings

IMPL Stock Data

5.76M
7.99M
0.52%
71.62%
3.56%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Seattle

About IMPL

impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.